Skip to search formSkip to main contentSkip to account menu

2 ML eribulin mesylate 0.5 MG/ML Injection [Halaven]

Known as: Halaven 1 MG per 2 ML Injection, 2 ML Halaven 0.5 MG/ML Injection, Halaven 1 MG in 2 ML Injection 
National Institutes of Health

Related topics

Related topics

6 relations
EthanolHalavenInjectionWater

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.
2016
2016
HALAVEN® (eribulin mesylate) injection, for intravenous use
  • 2016
  • Corpus ID: 3194728
INDICATIONS AND USAGE HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: • Metastatic breast cancer… 
Review
2016
Review
2016
Clinical benefit of eribulin (Halaven®) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms.
2016
2016
Abstract P1-03-09: Pegylated recombinant human hyaluronidase PH20 (PEGPH20) enhances efficacy of eribulin mesylate (HALAVEN®) in triple negative breast cancer xenografts
Hyaluronan (hyaluronic acid, HA), a glycosaminoglycan found in tissue throughout the body, overaccumulates in the tumor… 
2016
2016
Eribulin mesylate in previously treated patients with advanced liposarcoma: a guide to its use
Eribulin mesylate (Halaven®), a synthetic analogue of halichondrin B, is a welcome addition to the therapeutic options for… 
2015
2015
Eribulin mesylát (Halaven ®) - nová naděje pro předléčené pacientky s pokročilým a metastatickým karcinomem prsu
Eribulin je netaxanový inhibitor dynamiky mikrotubulů. Je syntetickým analogem halichondrinu B. Působenim na mikrotubuly eribulin… 
2013
2013
Abstract B90: Eribulin mesylate alters immune homeostasis in mice bearing syngeneic tumors.
Numerous studies indicate that certain tumor-infiltrating macrophage subsets can support neoplastic growth. Recent reports showed… 
2013
2013
Abstract 899: Characterization and establishment of a drug-resistant human lung cancer model.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Introduction In 2012, lung cancer is expected to be… 
2012
2012
Eribulina (Halaven®): riesgo de errores de dosificación
Review
2011
Review
2011
[Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)